Director, Regulatory Policy and Intelligence Abbvie, Inc.
There are growing opportunities to leverage the use of AI technologies across the combination product lifecycle from nonclinical and clinical development to post-market surveillance for enhancing safety, efficacy, and quality. However, stakeholders are challenged with understanding emerging global regulatory frameworks on the use of AI and ensuring that AI models are developed responsibly. This session will explore industry and health authority use cases and perspectives on the safe and responsible adoption of AI technologies in the combination product lifecycle.
